---

---

sector : Professional, scientific, and technical services    crawled time : 12:00   

save search

---

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.41 5.26% 4.99% 390K |

Professional, Scientific, and T...

| 7.33% | O: 2.17% H: 5.06% C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy

---

Bright Mountain Media, Inc.'s Wholly Owned Subsidiary, Big Village, In Top 25 of Greenbook's Most Innovative Suppliers List
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
BMTM | $0.0541 3021.1% 29K |

Professional, Scientific, and T...

| Email alert Add to watchlist
wholly

---

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
CMPX | $1.51 1.34% 1.32% 72K |

Professional, Scientific, and T...

| -0.98% | O: 2.93% H: 3.8% C: -0.63%
ctx-8371 first tumors therapeutics study

---

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BRTX | $1.35 -2.17% -2.22% 89K |

Professional, Scientific, and T...

| 1.52% | O: 7.58% H: 16.2% C: -7.75%
brtx-100 fda clearance study

---

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ABOS | $3.15 0.64% 0.63% 270K |

Professional, Scientific, and T...

| -13.66% | O: -4.64% H: 3.15% C: 0.29%
acu193 first neurology biomarker pharmaceuticals for meeting

---

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
RXRX | $7.69 1.18% 1.17% 4.8M |

Professional, Scientific, and T...

| -8.33% | O: -9.4% H: 2.1% C: -0.53%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| 1.02% | O: -2.09% H: 0.0% C: 0.0%
commercial

---

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Published: 2024-04-12 (Crawled : 12:00) - globenewswire.com
CMPX | $1.51 1.34% 1.32% 72K |

Professional, Scientific, and T...

| -8.98% | O: -4.19% H: 9.38% C: 1.25%
conference therapeutics foundation

---

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
NAUT | $2.45 1.24% 1.22% 25K |

Professional, Scientific, and T...

| -2.73% | O: -1.56% H: 5.95% C: 4.37%
first financial results

---

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CMPX | $1.51 1.34% 1.32% 72K |

Professional, Scientific, and T...

| -12.39% | O: -8.93% H: 12.03% C: 1.27%
therapeutics

---

Bright Mountain Media, Inc. (OTCQB: BMTM) Leveraging AI for Advanced Audience Insights and Data Analysis. 
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BMTM | $0.0541 3021.1% 29K |

Professional, Scientific, and T...

| Email alert Add to watchlist
for advanced

---

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -3.83% | O: -3.83% H: 0.0% C: 0.0%
breast cancer preclinical for

---

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -2.13% | O: 1.77% H: 0.0% C: 0.0%
breast cancer system

---

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.35 -2.17% -2.22% 89K |

Professional, Scientific, and T...

| 0.75% | O: -1.5% H: 0.0% C: -2.29%
brtx-100 disease trial

---

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
TCRX | News 3 d | $7.23 1.55% 1.52% 210K |

Professional, Scientific, and T...

| 3.71% | O: 3.14% H: 1.8% C: 1.66%
medical therapeutics

---

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
AKYA | News | $3.82 -2.05% -2.09% 86K |

Professional, Scientific, and T...

| -13.21% | O: -4.33% H: 5.71% C: 3.81%
solutions meeting

---

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ABOS | $3.15 0.64% 0.63% 270K |

Professional, Scientific, and T...

| -17.28% | O: 4.19% H: 2.01% C: -3.52%
disease alzheimer’s treatment pharmaceuticals

---

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
VERA | $39.46 0.84% 0.84% 1.2M |

Professional, Scientific, and T...

| -7.07% | O: -3.66% H: 0.0% C: 0.0%
congress association renal therapeutics

---

HealthLynked Announces Fourth Quarter and Full Year 2023 Results Highlighted by 70% Reduction in Net Loss for Q4
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
HLYK | $0.0547 18.98% 5.4K |

Professional, Scientific, and T...

| -4.76% | O: -8.73% H: 14.43% C: -9.48%
year results

---

Recursion to Participate in Upcoming Investor Conference
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
RXRX | $7.69 1.18% 1.17% 4.8M |

Professional, Scientific, and T...

| -22.54% | O: -9.86% H: 0.45% C: -2.12%
conference

---

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
TCRX | News 3 d | $7.23 1.55% 1.52% 210K |

Professional, Scientific, and T...

| -10.32% | O: -1.3% H: 0.0% C: -9.89%
conference presentation therapeutics

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---